BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
36.85
+0.05 (0.12%)
At close: Feb 21, 2025, 4:00 PM
36.81
-0.04 (-0.11%)
After-hours: Feb 21, 2025, 4:00 PM EST
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for BridgeBio Pharma stock have an average target of 52.27, with a low estimate of 43 and a high estimate of 95. The average target predicts an increase of 41.85% from the current stock price of 36.85.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 6 | 6 | 6 | 6 | 6 |
| Hold | 1 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 13 | 13 | 13 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $45 → $49 | Strong Buy | Maintains | $45 → $49 | +32.97% | Feb 21, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $95 | Buy | Reiterates | $95 | +157.80% | Feb 21, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $49 → $52 | Buy | Maintains | $49 → $52 | +41.11% | Feb 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $49 | Strong Buy | Reiterates | $49 | +32.97% | Feb 13, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $48 → $49 | Buy | Maintains | $48 → $49 | +32.97% | Feb 12, 2025 |
Financial Forecast
Revenue This Year
223.90M
from 9.30M
Increased by 2,306.75%
Revenue Next Year
188.12M
from 223.90M
Decreased by -15.98%
EPS This Year
-2.62
from -3.95
EPS Next Year
-3.73
from -2.62
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 244.2M | 360.2M | 781.4M | |||
| Avg | 223.9M | 188.1M | 458.4M | |||
| Low | 211.7M | 55.8M | 218.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2,524.4% | 60.9% | 315.4% | |||
| Avg | 2,306.8% | -16.0% | 143.7% | |||
| Low | 2,175.4% | -75.1% | 16.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.12 | -2.82 | -1.05 | |||
| Avg | -2.62 | -3.73 | -2.80 | |||
| Low | -2.83 | -4.42 | -3.75 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.